These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34131166)

  • 1. Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells.
    KalantarMotamedi Y; Ejeian F; Sabouhi F; Bahmani L; Nejati AS; Bhagwat AM; Ahadi AM; Tafreshi AP; Nasr-Esfahani MH; Bender A
    Sci Rep; 2021 Jun; 11(1):12537. PubMed ID: 34131166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia.
    Liang C; Qiao G; Liu Y; Tian L; Hui N; Li J; Ma Y; Li H; Zhao Q; Cao W; Liu H; Ren X
    Eur J Med Chem; 2021 Aug; 220():113451. PubMed ID: 33895500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evidence of all-trans retinoic acid inducing maturation in acute promyelocytic leukaemia.
    Hamidah HN; Cheong SK; Ainoon O
    Acta Haematol; 1993; 89(1):50-1. PubMed ID: 8480488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify
    Lee LM; Christodoulou EG; Shyamsunder P; Chen BJ; Lee KL; Fung TK; So CWE; Wong GC; Petretto E; Rackham OJL; Tiong Ong S
    Oncogene; 2022 Nov; 41(48):5160-5175. PubMed ID: 36271030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid in the treatment of acute promyelocytic leukaemia.
    White KL; Wiley JS; Frost T; McKendrick JJ; Hermann RP; Seldon M; Enno A; Bell R; Bunce I; Taylor K
    Aust N Z J Med; 1992 Oct; 22(5):449-54. PubMed ID: 1445034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid in acute promyelocytic leukaemia.
    Avvisati G; Tallman MS
    Best Pract Res Clin Haematol; 2003 Sep; 16(3):419-32. PubMed ID: 12935960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoic acids in the treatment of acute promyelocytic leukemia.
    Castaigne S; Chomienne C; Daniel MT; Berger R; Miclea JM; Ballerini P; Degos L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):36-8. PubMed ID: 2190178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.
    Gillis JC; Goa KL
    Drugs; 1995 Nov; 50(5):897-923. PubMed ID: 8586032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute promyelocytic leukaemia in the all trans retinoic acid era.
    DeLoughery TG; Goodnight SH
    Med Oncol; 1996 Dec; 13(4):233-40. PubMed ID: 9152974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
    Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
    Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy.
    Harrison P; Chipping P; Fothergill GA
    Br J Haematol; 1994 Mar; 86(3):681-2. PubMed ID: 8043456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro.
    Kim IS; Jin JY; Lee IH; Park SJ
    Br J Pharmacol; 2004 Jun; 142(4):749-55. PubMed ID: 15159275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
    Mi JQ; Chen SJ; Zhou GB; Yan XJ; Chen Z
    J Intern Med; 2015 Dec; 278(6):627-42. PubMed ID: 26058416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
    Wang ZY; Chen Z
    Lancet Oncol; 2000 Oct; 1():101-6. PubMed ID: 11905660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
    Salih HR; Starling GC; Brandl SF; Pelka-Fleischer R; Haferlach T; Hiddemann W; Kiener PA; Nuessler V
    Br J Haematol; 2002 Apr; 117(1):76-85. PubMed ID: 11918536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia.
    Olwill SA; McGlynn H; Gilmore WS; Alexander HD
    Br J Haematol; 2005 Oct; 131(2):258-64. PubMed ID: 16197459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].
    Tøstesen M; Østgård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
    Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History of promyelocytic leukaemia.
    Bernard J
    Leukemia; 1994; 8 Suppl 2():S1-5. PubMed ID: 7815829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.